Sign up online today & collaborate
or click here to find out more
Daiichi Sankyo and Plexxikon’s investigational rare cancer drug PLX3397 has lead to prolonged tumour regressions in its Phase 1 trial.
PLX3397 is a CSF-1R inhibitor for the treatment of tenosynovial giant cell tumor (TGCT) – a rare type of cancer that affects the joints or tendon sheath and can lead to loss of mobility. There is currently no systematic therapy approved for TGCT.
The trial results, published in the New England Journal of Medicine, showed that 52% of patients achieved a partial response and 30% had stable disease.
For more click here
Source: Pharma Times